The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.
Tumor necrosis factor (TNF) is a macrophage product under active study as an anticancer drug. However, this agent can be very toxic and has been implicated in the pathogenesis of endotoxic shock. After intravenous injection of human recombinant TNF (4 micrograms/g), growing rats showed an unusual constellation of physiological responses, and all died within 2-4 hr. In 1 hr, TNF caused a sharp fall (2.5 degrees C) in body temperature and a large increase in plasma prostaglandin E2 levels. Blood glucose initially increased, but then a profound hypoglycemia developed by 2 hr. The TNF-treated animals also showed diarrhea, cyanosis, and a severe metabolic acidosis. A single injection of the cyclooxygenase inhibitors indomethacin or ibuprofen before the TNF treatment completely prevented the rapid killing and reduced eventual lethality by 70%. These agents blocked prostaglandin E2 production and prevented the hypothermia, changes in blood glucose, acidosis, and other symptoms. Since similar physiological changes have been reported after endotoxin injection, our data support the suggestion that TNF production is a critical factor in the development of septic shock. These findings also indicate that increased production of prostaglandins or thromboxanes is important in endotoxic shock and argue that cyclooxygenase inhibitors should be useful in its therapy. Indomethacin did not block the cytotoxic effects of TNF in vitro on several transformed cell lines (HeLa, Me 180, or L929). Therefore, combined use of TNF with a cyclooxygenase inhibitor may allow safer administration of high doses of this polypeptide to cancer patients.
D000818:Animals; D000970:Antineoplastic Agents; D001831:Body Temperature / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors; D003603:Cytotoxins / Q000633:toxicity*; D004731:Endotoxins / Q000633:toxicity; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000627:therapeutic use / Q000633:toxicity*; D007052:Ibuprofen / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D051381:Rats; D014409:Tumor Necrosis Factor-alpha
D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D003603:Cytotoxins; D004731:Endotoxins; D006023:Glycoproteins; D014409:Tumor Necrosis Factor-alpha; D007052:Ibuprofen; D007213:Indomethacin